These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city. Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958 [TBL] [Abstract][Full Text] [Related]
27. Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis. Fujiwara S; Mimura N; Yoshimura H; Fujimoto D; Ito M; Mori R; Ito J; Tomii K; Kawamoto M; Kohara N Intern Med; 2019 Oct; 58(19):2871-2874. PubMed ID: 31243206 [TBL] [Abstract][Full Text] [Related]
28. Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder? Ramakrishnan P Med Hypotheses; 2021 Jan; 146():110450. PubMed ID: 33309338 [TBL] [Abstract][Full Text] [Related]
31. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD. Lin L; Wu Y; Hang H; Lu J; Ding Y Front Immunol; 2022; 13():853891. PubMed ID: 35898513 [TBL] [Abstract][Full Text] [Related]
35. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort. Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910 [TBL] [Abstract][Full Text] [Related]